Compare Davita Inc (DVA) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Invesco Ltd. — how do they compare? Davita Inc trades at $179.44 (market cap $11.29B), while Invesco Ltd. trades at $29.59 (market cap $13.28B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.86% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Invesco Ltd. for 77 Days on average.
| DVA | IVZ | |
|---|---|---|
Market Cap | $11.29B | $13.28B |
Volume | 582,204 | 3,698,033 |
Sector | Health | Financials |
52-Week High | $240.96 | $33.31 |
52-Week Low | $103.87 | $22.44 |
Typical Hold Time | 113 Days | 77 Days |
Enterprise Value | $24.01B | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Invesco (IVZ) trades at $30.50, up 0.39% on the day, with a mixed technical outlook showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $281.7 million for 2025 despite revenue growth to $6.38 billion, with profitability metrics like ROE at -2.97% indicating challenges. Recent news highlights the expansion of its QQQ ETF suite and a dividend declaration, while analyst consensus remains cautiously optimistic with a $33.71 price target.
The outlook for IVZ hinges on reversing negative earnings trends and capitalizing on ETF growth initiatives. Key opportunities include strong asset under management growth and product innovation, but risks persist from competitive pressures and market volatility. Investors should weigh the potential for operational improvement against ongoing profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
